Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
Earnings Data
Report Date
Aug 07, 2025Before Open (Confirmed)
Period Ending
2025 (Q2)Consensus EPS Forecast
0.4Last Year’s EPS
0.32Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance in 2024 with significant revenue and profit growth, driven by the success of commercialized medicines like EPKINLY and TIVDAK. The company has a robust pipeline with strategic investments and provided optimistic guidance for 2025. However, there are minor concerns about EPKINLY's flat sales in Q4 and the company's dependency on key products amid competitive pressures.Company Guidance -
Q2 2025
Strong Revenue and Profit Growth
Genmab achieved a 31% total revenue growth in 2024, driven by the success of its commercialized medicines, including EPKINLY and TIVDAK. The company also grew operating profit by 26% and ended the year with nearly $3 billion in cash.
EPKINLY's Market Expansion
EPKINLY received multiple regulatory approvals and achieved $281 million in sales for 2024, driven by strong performance in the U.S. and Japan. The drug is expected to have a peak sales opportunity exceeding $3 billion.
Pipeline and Strategic Investments
Genmab has 12 products in 30 clinical trials, including seven Phase III trials. The company made strategic investments such as the $1.8 billion acquisition of ProfoundBio to accelerate development.
TIVDAK's Continued Growth
TIVDAK achieved $131 million in sales during 2024 and is regarded as the global standard of care in second-line plus recurrent or metastatic cervical cancer.
Robust Financial Guidance for 2025
Genmab provided 2025 guidance with expected revenue growth of 12% at the midpoint and a recurring revenue growth of 18%.
GMAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GMAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $20.60 | $19.42 | -5.73% |
Feb 12, 2025 | $18.89 | $19.69 | +4.24% |
Nov 06, 2024 | $22.75 | $22.33 | -1.85% |
Aug 08, 2024 | $26.46 | $27.07 | +2.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Genmab A/S (GMAB) report earnings?
Genmab A/S (GMAB) is schdueled to report earning on Aug 07, 2025, Before Open (Confirmed).
What is Genmab A/S (GMAB) earnings time?
Genmab A/S (GMAB) earnings time is at Aug 07, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GMAB EPS forecast?
GMAB EPS forecast for the fiscal quarter 2025 (Q2) is 0.4.